Breaking

A Cancer-Fighting Version of Herpes Shows Promise in Early Human Trial - Gizmodo
Sep 23, 2022 58 secs
In preliminary data from a Phase I trial, a genetically modified version of the herpes virus has shown promise in treating difficult-to-eradicate tumors, with one patient having experienced a complete remission for 15 months so far.

The viral treatment is known as RP2 and is a genetically engineered strain of herpes simplex 1, the virus responsible for most cases of oral herpes in humans, as well as some cases of genital herpes.

Injected directly into the tumor, the virus is supposed to selectively infect and kill certain cancer cells.

In a Phase I trial conducted by scientists at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in the UK, RP2 was given as the only treatment to nine patients with advanced cancers that failed to respond to other therapies; it was also given in combination with another immunotherapy drug to 30 patients.

“Our study shows that a genetically engineered, cancer-killing virus can deliver a one-two punch against tumors—directly destroying cancer cells from within while also calling in the immune system against them,” said lead author Kevin Harrington, professor of Biological Cancer Therapies at The Institute of Cancer Research, in a statement from the organization.

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED